September 2026 brought major expert-evidence hearings in the GLP-1 and Depo-Provera multidistrict litigations, plus active settlement-administration orders in the Depo-Provera case. It also brought urgent federal safety notices involving recalled medical applicators and Sauna360 saunas. A multidistrict litigation, or MDL, groups similar federal lawsuits before one judge for coordinated pretrial work. These developments affect people evaluating potential injury claims, existing claimants, health-care providers, and product owners.
Table of Contents
- GLP-1 litigation reaches a key expert-evidence stage
- Depo-Provera MDL combines litigation hearings and settlement infrastructure
- Consolidation requests can change before a hearing
- FDA notice makes recalled medical applicators an immediate provider issue
- Sauna owners should stop ordinary use until they obtain the offered repair
GLP-1 litigation reaches a key expert-evidence stage
Judge Karen Marston held a September 14–18 Rule 702/Daubert hearing in GLP-1 MDL 3094. The hearing addressed cross-cutting expert issues in lawsuits alleging gastrointestinal injuries associated with Ozempic, Wegovy, Rybelsus, Trulicity, or Mounjaro, according to the U.S. District Court for the Eastern District of Pennsylvania's MDL notice.
Rule 702 and Daubert proceedings determine whether proposed expert testimony meets the standards for admission in court. That makes the hearing consequential because expert evidence can shape how plaintiffs attempt to prove injury and causation. The defendants, Novo Nordisk and Eli Lilly, deny that the drugs cause gastroparesis or other gastrointestinal injuries and deny that warnings were inadequate. The court's hearing therefore addresses admissibility of evidence, not whether any particular plaintiff has proved causation or liability.
Depo-Provera MDL combines litigation hearings and settlement infrastructure
The Depo-Provera MDL court listed a September 18 case-management conference followed by a Rule 702 motions hearing. The litigation concerns allegations that injectable Depo-Provera or generic versions caused intracranial meningiomas, while defendants maintain the medication is safe and effective, according to the Northern District of Florida's MDL description. The court also entered September 4 orders appointing a lien-resolution master, a qualified-settlement-fund administrator, and a supplemental-compensation-fund allocation master.
Those appointments create administrative capacity for handling liens, funds, and allocations while the litigation continues, as shown in the Northern District of Florida's orders by date. For current or potential claimants, this is a reason to organize records rather than assume a personal recovery is established. Useful materials can include prescribing and pharmacy records, imaging and diagnosis records, treatment information, and documentation of insurance or benefit liens.
Consolidation requests can change before a hearing
The Judicial Panel on Multidistrict Litigation scheduled a September 24 Chicago hearing session, but vacated the hearing-session order for MDL 3196 after treating the motion as withdrawn. The development shows that proposed MDLs can change substantially before argument, according to the JPML hearing information page. For people following a developing mass tort, a proposed consolidation is not the same as an established MDL.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
The procedural status matters because it affects where cases may be coordinated and how quickly common pretrial proceedings develop. AFFF/PFAS litigation remains an important exposure-based category. A JPML transfer order described shared questions involving AFFF use, PFAS toxicity, health effects, groundwater migration, and alleged exposure through contaminated drinking water.
FDA notice makes recalled medical applicators an immediate provider issue
FDA's September MedSun newsletter highlighted hospital-kit alerts involving recalled BD ChloraPrep applicators. FDA's underlying recall notice says fungal contamination may cause serious systemic infection, sepsis, illness, or death, making rapid product identification and discontinuation important for affected providers and facilities under the FDA recall notice.
This notice is not a mass-tort court filing, but it is directly relevant to injury-risk assessment. A patient who suspects exposure should preserve information identifying the facility, procedure date, product name, lot information if available, and medical treatment connected to a possible infection.
Sauna owners should stop ordinary use until they obtain the offered repair
On September 17, the Consumer Product Safety Commission recalled about 41,580 Sauna360 infrared saunas, hybrid saunas, and infrared kits. The agency said panels can short-circuit and overheat, creating fire and burn hazards, and directed owners toward the offered repair in its Sauna360 recall notice. Owners should take practical steps now:.
- Identify the model and purchase details.
- Stop ordinary use while arranging the offered repair.
- Keep photographs of the unit, any damage, and proof of purchase.
- Seek prompt medical care for a burn or smoke-related injury.
You Might Also Like
- What Is New With Pharmaceutical Lawsuits Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- What Is New With Eligibility Tools Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- What Is New With Demographic Guides Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways